Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

CTLA-4 collaboration
June 2017
SHARING OPTIONS:

SANTA CLARA, Calif.—Early May saw Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International, share news that it was collaborating with Jiangsu Qyun Bio-Pharmaceutical Co. Ltd. to develop a CTLA-4 antibody. The companies will seek to develop a less toxic CTLA-4 antibody and better combination strategies to address the adverse effects due to T cell activation and proliferation seen in some patients receiving anti-CTLA-4 immunotherapies. Under the agreement, CrownBio will apply Jiangsu Qyun Bio-Pharmaceutical’s expertise to support the IND application and further clinical development of the former’s 10B10 antibody.
 
“The collaboration agreement between CrownBio and Jiangsu Qyun Bio-Pharmaceutical Co. Ltd is indicative of our focus on innovation and enhances our portfolio in immuno-oncology,” said Jean-Pierre Wery, CEO of CrownBio. “Moreover, this partnership highlights CrownBio’s commitment to develop therapies that could significantly impact the way cancer is treated.”

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2017 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.